Dr Kevin Rouault-Pierre

BSc, MSc, PhD
Lecturer
Group Leader
Research Focus

My main research interests are in haematopoietic stem cells and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.

Key Publications

Preclinical modeling of myelodysplastic syndromes. Leukemia (2017) 31(12):2702-2708. PMID: 28663577

Myelodysplastic synrome can propagate from the multipotent progenitor compartment. Haematologica (2016) 102(1):e7-e10. PMID: PMC5210239

SF3B1 mutant MDS initiating-cells may arise from the haematopoietic stem cell compartment. Nature Communications (2015) 6:10004. PMID: 26643973

HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. Cell Stem Cell (2013) 13(5):549-63. PMID: 24095676

Major Funding
  • 2022-2025- Barts Charity, Project Grant, £237,000
  • 2022-2023- British Society of Haematology, Early Stage Research grants support, £20,000
  • 2021-2022- Lady Tata Memorial Trust awarded to Celine Philippe (Postdoctoral Fellow), £40,000
  • 2019-2022- Academy of Medical Sciences Springboard Award, £100,000
  • 2017-2022- Kay Kendall Leukaemia Fund, £292,000
Other Activities
  • Member of the British Society of Haematology
  • Member of the European Haematology Association
  • Member of the Société Française d'Hématologie
Research

Myelodysplastic Syndromes (MDS) and Acute myeloid leukaemia (AML) are both clonal diseases that harbour MDS stem cells (MDS-SC) and pre-leukemic cells, respectively. Various studies have demonstrated that acquired mutations in haematopoietic cells' genes can lead to clonal fitness and eventually to propagation of the disease. Understanding the switch between clonal haematopoiesis and clonal disease is one of the major challenges of the scientific community, which highlights the need to unravel how epigenetic/spliceosome stresses are integrated by stem cells and dictate their clonal fate.

In the lab we develop in-vitro and in-vivo modelling of MDS and AML diseases. Using primary human samples and multi-omics approaches including RNAseq (Bulk & single cell), Proteomics, Phosphoproteomics, Metabolomics and drug screening, we challenge normal and malignant haematopoiesis to unveil new therapeutic targets in myeloid malignancies.

Key words: Stem cells, patient samples, AML, MDS, splicing, RNA biology, metabolism and translation regulation.


Prizes from the group for Poster and Oral communications:

  • September 2021: Oral presentation by Doriana Di Bella (PhD student) at the Barts Cancer Institute PhD Day, Won the Prize for the best oral presentation (AML & Microenvironment)
  • October 2021: Oral presentation by Celine Philippe (Postdoctoral Fellow) at the annual conference of Hematology and Oncology, France. Won the Prize for the best presentation (Splicing & MDS)
  • October 2021: Poster presentation (KRP) at the Endoplasmic Reticulum Symposium, France. Poster Prize.
Other Activities
  • Member of the British Society of Haematology
  • Member of the European Haematology Association
  • Member of the Société Française d'Hématologie
Major Funding
  • 2022-2025- Barts Charity, Project Grant, £237,000
  • 2022-2023- British Society of Haematology, Early Stage Research grants support, £20,000
  • 2021-2022- Lady Tata Memorial Trust awarded to Celine Philippe (Postdoctoral Fellow), £40,000
  • 2019-2022- Academy of Medical Sciences Springboard Award, £100,000
  • 2017-2022- Kay Kendall Leukaemia Fund, £292,000
Recent Publications

A dual role for the RNA helicase DHX34 in NMD and pre-mRNA splicing and its function in hematopoietic differentiation Hug N, Aitken S, Longman D et al. RNA (2022) 28(7) 1224-1238

HNRNPA2B1 controls an unfolded protein response-related prognostic gene signature in prostate cancer Foster J, Gea E, Labiba M et al. (2022) (18)

A dual role for the RNA helicase DHX34 in NMD and pre-mRNA splicing and its function in hematopoietic differentiation Hug N, Aitken S, Longman D et al. (2022) (18)

Acquired somatic variants in inherited myeloid malignancies Armes H, Rio-Machin A, Krizsán S et al. Leukemia (2022) 36(7) 1377-1381

Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment Pedicona F, Casado P, Hijazi M et al. Science Signaling (2022) 15(7)

Splicing Factor Mutations and Disease Phenotype: Searching for a Needle in a Haystack Rouault-Pierre K HemaSphere (2021) 5(7) E587

Ectopic Humanized Mesenchymal Niche in Mice Enables Robust Engraftment of Myelodysplastic Stem Cells Mian SA, Abarrategi A, Kong KL et al. Cancer discovery (2021) 2(7) 135-145

ER stress and unfolded protein response in leukemia: Friend, foe, or both? Féral K, Jaud M, Philippe C et al. Biomolecules (2021) 11(7) 1-31

Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis Rosu A, Hachem NE, Rapino F et al. Journal of Experimental Medicine (2021) 218(7)

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia Rio-Machin A, Casado-Izquierdo P, Miettinen J et al. Blood (2020) 136(10) 39-40

For additional publications, please click here
Team

Posdoctoral Researchers
Dr Celine Philippe

PhD students
Doriana Di Bella, Weiwei Tang

Biography

I have been developing my expertise on haematopoietic stem cells and multiple cancer fields throughout my career and have beneficiated in particular of the Francis Crick Institute’s world-class environment, with one of the world leaders in the haematology and stem cell field, Dr Dominique Bonnet. The work conducted in Dr Bonnet’s group in collaboration with Prof Mufti from King’s College Hospital has significantly contributed to providing me with the tools and knowledge for the project I am developing.

In September 2017 I was awarded the Kay Kendall Leukaemia intermediate fellowship and joined the Barts Cancer Institute at the Centre for Haemato-Oncology led by Prof John Gribben.

Address

Barts Cancer Institute,
Queen Mary University of London,
Charterhouse Square,
London EC1M 6BQ

Email address: bci-admin@qmul.ac.uk
Telephone: +44 20 7882 5555

Upcoming Events

© 2013 ~ 2022 Cancer Research UK Barts Centre